- $137.40m
- $131.64m
Brief: Enlivex Announces Dosing Of First Patient Under Phase II Trial For Allocetra
Enlivex rises on US patent for cell therapy
Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering The Use Of Allocetra™ In Patients Receiving Car T-Cell Therapy
Brief: Enlivex Appoints Andrew Singer To Its Board Of Directors
Brief: Enlivex Receives Positive Dsmb Recommendation And Imoh Clearance To Continue Phase I/Ii Trial Of Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers
Brief: Enlivex Announces Positive Dsmb Recommendation And Imoh Clearance To Continue Phase I/Ii Trial Of Allocetra In Patients With Advanced Solid Tumors
Brief: Enlivex Authorizes To Expand Phase II Sepsis Clinical Trial In France, Belgium
Brief: Enlivex Says May Elect To Sell Ordinary Shares Of Up To $100 Million
Brief: Enlivex Therapeutics Says Qtrly Net Loss Was $5.7 Mln, Compared To Net Loss Of $3.4 Mln For Q3 2021
Brief: Arix Bioscience Says Portfolio Co Imara Announces Merger Deal With Enliven Therapeutics
Brief: Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering The Use Of Allocetra™ To Prevent Cytokine Release Syndrome In Patients Receiving Car T Cell Therapy
Brief: Enlivex Receives Notice Of Allowance For Japanese Patent Application Covering Allocetra Derived From Pooled Donor Cells
Enlivex rises on regulatory clearance for changes to sepsis therapy trial
Brief: Enlivex Announces Regulatory Clearance In Multiple Countries For Integration Of Frozen Allocetra Formulation And Expansion Of Patient Population In Its Sepsis Phase II Clinical Trial
Brief: Enlivex Announces Second Quarter 2022 Financial Results And Provides Business Update
Brief: Enlivex receives israeli ministry of health approval for the initiation of a Phase I/Ii Trial Evaluating Allocetra™
Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Methods Of Treating Sepsis With Allocetra™
Brief: Sheba Medical Center And Enlivex Announce Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Combined With Chemotherapy